Warfin 2.0: New Developments in Anti-Coagulation Therapy -- Discussions http://www.scivee.tv/node/28922 Warfin 2.0: New Developments in Anti-Coagulation Therapy Warfin 2.0: New Developments in Anti-Coagulation Therapy Slides http://www.scivee.tv/node/28922/talks/2224/last Here is the slides for our group! May 10, 2011 http://www.scivee.tv/node/28922/talks/2224/last Slides? http://www.scivee.tv/node/28922/talks/2223/last Sorry if we discussed this before but where are the slides? May 10, 2011 http://www.scivee.tv/node/28922/talks/2223/last Pradaxa Power Point Review http://www.scivee.tv/node/28922/talks/2201/last Review for - Pradaxa: Let there be an answer Reviewed by: Angela Bougetz, Irina Gutman, and Karen Hoang Overall value of the presentation to the intended audience The overall presentation provides useful and relevant information about an alternative to Warfarin. The presentation describes the disease, the current use of anticoagulant and the issues with currently using Warfarin. After emphasizing the severe side effects of Warfarin, the presentation goes on to give an alternative, Pradaxa, to Warfarin. They go on to discuss how to convert from Warfarin to Pradaxa along with dosing, side effects, contraindications and pharmacokinetics of Pradaxa. The presentation also addresses special populations regarding Pradaxa, as well as patient counseling points. Major points that should be addressed in the final PowerPoint presentation Title: Target audience and purpose of the presentation are unclear from the title. Audience: The level of the presentation is too technical for the general public. Health care professionals would understand the presentation; however, if the target audience is the general public, layman’s terms should be used throughout the entire presentation. Some information (pharmacokinetics) can be omitted or presented in a simple way for the general public. Mechanism of Action: This portion should be simplified or omitted depending on what the goal for the audience is. Emphasize in the end to contact your doctor or pharmacist to find out if Pradaxa is a suitable option for each individual. Minor points to be addressed Slide 9 – Image of the protein can be omitted. Slide 12 – Expectations if you do choose to convert. What will happen during the conversion time? Omit CrCL level info (too technical for general public). Slide 16 – Suggestion for the title: Special Populations. You combine both populations who can and cannot use Pradaxa, and the current title is a bit confusing. Slide 17 – Bioavailability and Half-life really is not relevant. Possibly restate that the drug will be out of your body in t1/2 Overall, the slide titles need to be in layman’s terms. (For example slide 13 – contraindications). Apr 26, 2011 http://www.scivee.tv/node/28922/talks/2201/last